1. Scrip
  2. >>Business
  3. >>Financing

Interview: Achilles Advances Armed With £100m

 
• By Kevin Grogan

After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.

Achilleon
Achilles showing no sign of weakness • Source: Shutterstock

At a time when UK biotechs have struggled to access funds, Achilles Therapeutics Ltd. has bucked the trend, raising an impressive £100m to advance its personalized cancer immunotherapies targeting clonal neoantigens into the clinic.

New investor RA Capital led the series B round which included founding backer Syncona additional new investors Forbion Capital Partners,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business